Donna Elizabeth Maziak

Prof. Dr. Donna Elizabeth Maziak

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Cancer Detection Prevention
Verified
Journal Article
Closed access
DMDonna Elizabeth Maziak
Donna Elizabeth Maziak
MDMinh T. Do
Minh T. Do
FSFarid M. Shamji
Farid M. Shamji
SSSudhir R. Sundaresan
Sudhir R. Sundaresan
DPD. Garth Perkins
D. Garth Perkins
PWPatrick T.T. Wong
Patrick T.T. Wong

8 April 2014 in Critical Care
Verified
Journal Article
Open access
PDF file
ASAndrew Seely
Andrew Seely
ABAndrea Bravi
Andrea Bravi
CHChristophe Herry
Christophe Herry
GGGeoffrey Green
Geoffrey Green
Longtin AndréLongtin André
Longtin André
JMJohn C Marshall
John C Marshall
Introduction: Prolonged ventilation and failed extubation are associated with increased harm and cost. The added value of heart and respiratory rate variability (HRV and RRV) during spontaneous breathing trials (SBTs) to predict extubation failure remains unknown. Methods: We enrolled 721 patients in a multicenter (12 sites), prospective, observational study, evaluating clinical estimates of risk of extubation failure, physiologic measures recorded during SBTs, HRV and RRV recorded before and during the last SBT prior to extubation, and extubation outcomes. We excluded 287 patients because of protocol or technical violations, or poor data quality. Measures of variability (97 HRV, 82 RRV) were calculated from electrocardiogram and capnography waveforms followed by automated cleaning and variability analysis using Continuous Individualized Multiorgan Variability Analysis (CIMVA™) software. Repeated randomized subsampling with training, validation, and testing were used to derive and compare predictive models. Results: Of 434 patients with high-quality data, 51 (12%) failed extubation. Two HRV and eight RRV measures showed statistically significant association with extubation failure (P 0.5 in patients with RSBI >105 and perceived high risk of failure yielded a fold increase in risk of extubation failure of 3.0 (95% confidence interval (CI) 1.2 to 5.2) and 3.5 (95% CI 1.9 to 5.4), respectively. Conclusions: Altered HRV and RRV (during the SBT prior to extubation) are significantly associated with extubation failure. A predictive model using RRV during the last SBT provided optimal accuracy of prediction in all patients, with improved accuracy when combined with clinical impression or RSBI. This model requires a validation cohort to evaluate accuracy and generalizability. Trial registration: ClinicalTrials.gov NCT01237886. Registered 13 October 2010.

1 May 2018 in Thoracic Surgery Clinics
Verified
Journal Article
Closed access
DMDonna Elizabeth Maziak
Donna Elizabeth Maziak

29 January 2020 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
CHCandyce Hamel
Candyce Hamel
NANadera Ahmadzai
Nadera Ahmadzai
ABAndrew Beck
Andrew Beck
MTMicere Thuku
Micere Thuku
BSBecky Skidmore
Becky Skidmore
ASAdrienne Stevens
Adrienne Stevens
Background: Two reviews and an overview were produced for the Canadian Task Force on Preventive Health Care guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease (GERD) without alarm symptoms. The goal was to systematically review three key questions (KQs): (1) The effectiveness of screening for these conditions; (2) How adults with chronic GERD weigh the benefits and harms of screening, and what factors contribute to their preferences and decision to undergo screening; and (3) Treatment options for Barrett’s esophagus (BE), dysplasia or stage 1 EAC (overview of reviews). Methods: Bibliographic databases (e.g. Ovid MEDLINE®) were searched for each review in October 2018. We also searched for unpublished literature (e.g. relevant websites). The liberal accelerated approach was used for title and abstract screening. Two reviewers independently screened full-text articles. Data extraction and risk of bias assessments were completed by one reviewer and verified by another reviewer (KQ1 and 2). Quality assessments were completed by two reviewers independently in duplicate (KQ3). Disagreements were resolved through discussion. We used various risk of bias tools suitable for study design. The GRADE framework was used for rating the certainty of the evidence. Results: Ten studies evaluated the effectiveness of screening. One retrospective study reported no difference in long-term survival (approximately 6 to 12 years) between those who had a prior esophagogastroduodenoscopy and those who had not (adjusted HR 0.93, 95% confidence interval (CI) 0.58–1.50). Though there may be higher odds of a stage 1 diagnosis than a more advanced diagnosis (stage 2–4) if an EGD had been performed in the previous 5 years (OR 2.27, 95% CI 1.00–7.67). Seven studies compared different screening modalities, and showed little difference between modalities. Three studies reported on patients’ unwillingness to be screened (e.g. due to anxiety, fear of gagging). Eleven systematic reviews evaluated treatment modalities, providing some evidence of early treatment effect for some outcomes. Conclusions: Little evidence exists on the effectiveness of screening and values and preferences to screening. Many treatment modalities have been evaluated, but studies are small. Overall, there is uncertainty in understanding the effectiveness of screening and early treatments. Systematic review registrations: PROSPERO (CRD42017049993 [KQ1], CRD42017050014 [KQ2], CRD42018084825 [KQ3]).

1 October 2020 in Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
Verified
Journal Article
Closed access
SLStephen Lam
Stephen Lam
HBHeather Bryant
Heather Bryant
LDLaura Donahoe
Laura Donahoe
ADAshleigh Domingo
Ashleigh Domingo
CECraig Earle
Craig Earle
KYKazuhiro Yasufuku
Kazuhiro Yasufuku
RATIONALE: Appropriate management of low-dose computed tomography (LDCT) screening detected lung nodules will have significant implications for health care resource utilization and minimizing harm from radiation exposure related to imaging studies, invasive procedures and clinically significant distress.

6 December 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
James TankelJames Tankel
James Tankel
JSJonathan D. Spicer
Jonathan D. Spicer
QCQuincy Chu
Quincy Chu
PFPierre Olivier Fiset
Pierre Olivier Fiset
K Biniam Kidane
Biniam Kidane
NBNormand Blais
Normand Blais
The treatment paradigm for patients with stage II/III non-small-cell lung cancer (NSCLC) is rapidly evolving. We performed a modified Delphi process culminating at the Early-stage Lung cancer International eXpert Retreat (ELIXR23) meeting held in Montreal, Canada, in June 2023. Participants included medical and radiation oncologists, thoracic surgeons and pathologists from across Quebec. Statements relating to diagnosis and treatment paradigms in the preoperative, operative and postoperative time periods were generated and modified until all held a high level of consensus. These statements are aimed to help guide clinicians involved in the treatment of patients with stage II/III NSCLC.